Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/177264
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Soldevila, Laura | - |
dc.contributor.author | Villanueva, Bernat | - |
dc.contributor.author | Ulldemolins, Marta | - |
dc.contributor.author | Benavent Palomares, Eva | - |
dc.contributor.author | Padullés Zamora, Ariadna | - |
dc.contributor.author | Ribera Puig, Alba | - |
dc.contributor.author | Borras, Irene | - |
dc.contributor.author | Ariza Cardenal, Javier | - |
dc.contributor.author | Murillo Rubio, Óscar | - |
dc.date.accessioned | 2021-05-13T12:46:30Z | - |
dc.date.available | 2021-05-13T12:46:30Z | - |
dc.date.issued | 2021-04-16 | - |
dc.identifier.uri | http://hdl.handle.net/2445/177264 | - |
dc.description.abstract | Background: Daptomycin-induced eosinophilic pneumonia (DEP) is a rare but severe adverse effect and the risk factors are unknown. The aim of this study was to determine risk factors for DEP. Methods: A retrospective cohort study was performed at the Bone and Joint Infection Unit of the Hospital Universitari Bellvitge (January 2014-December 2018). To identify risk factors for DEP, cases were divided into two groups: those who developed DEP and those without DEP. Results: Among the whole cohort (n = 229) we identified 11 DEP cases (4.8%) and this percentage almost doubled in the subgroup of patients ≥70 years (8.1%). The risk factors for DEP were age ≥70 years (HR 10.19, 95%CI 1.28-80.93), therapy >14 days (7.71, 1.98-30.09) and total cumulative dose of daptomycin ≥10 g (5.30, 1.14-24.66). Conclusions: Clinicians should monitor cumulative daptomycin dosage to minimize DEP risk, and be cautious particularly in older patients when the total dose of daptomycin exceeds 10 g. | - |
dc.format.extent | 7 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/antibiotics10040446 | - |
dc.relation.ispartof | Antibiotics, 2021, vol. 10, num. 4 | - |
dc.relation.uri | https://doi.org/10.3390/antibiotics10040446 | - |
dc.rights | cc by (c) Soldevila et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | Pneumònia | - |
dc.subject.classification | Malalties bacterianes grampositives | - |
dc.subject.other | Pneumonia | - |
dc.subject.other | Gram-positive bacterial infections | - |
dc.title | Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 720014 | - |
dc.date.updated | 2021-05-13T12:11:38Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33923382 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
antibiotics-10-00446.pdf | 401.29 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License